Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases

Woo, 2009, Coronavirus diversity, phylogeny and interspecies jumping, Exp. Biol. Med., 234, 1117, 10.3181/0903-MR-94

Snijder, 2003, Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage, J. Mol. Biol., 331, 991, 10.1016/S0022-2836(03)00865-9

Dominguez, 2009, Detection of four human coronaviruses in respiratory infections in children: a one-year study in Colorado, J. Med. Virol., 81, 1597, 10.1002/jmv.21541

E.R. Gaunt, A. Hardie, E.C. Claas, P. Simmonds, K.E. Templeton, Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method, J. Clin. Microbiol., 48 2940–2947.

Rota, 2003, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, Science, 300, 1394, 10.1126/science.1085952

Marra, 2003, The genome sequence of the SARS-associated coronavirus, Science, 300, 1399, 10.1126/science.1085953

Yang, 2005, Design of wide-spectrum inhibitors targeting coronavirus main proteases, PLoS Biol., 3, e324, 10.1371/journal.pbio.0030324

Yang, 2006, Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor, J. Med. Chem., 49, 4971, 10.1021/jm0603926

Akaji, 2011, Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors, J. Med. Chem., 54, 7962, 10.1021/jm200870n

Santarsiero, 2005, Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors, J. Med. Chem., 48, 6767, 10.1021/jm050548m

Shie, 2005, Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic α,β-unsaturated esters, Bioorg. Med. Chem., 13, 5240, 10.1016/j.bmc.2005.05.065

Shao, 2008, Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease, Bioorg. Med. Chem., 16, 4652, 10.1016/j.bmc.2008.02.040

Lee, 2005, Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide, J. Mol. Biol., 353, 1137, 10.1016/j.jmb.2005.09.004

Chuck, 2010, Profiling of substrate specificity of SARS-CoV 3CLpro, PLoS ONE, 5, e13197, 10.1371/journal.pone.0013197

Chuck, 2011, Profiling of substrate specificities of 3C-like proteases from group 1, 2a, 2b, and 3 coronaviruses, PLoS ONE, 6, e27228, 10.1371/journal.pone.0027228

Huang, 2004, 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism, Biochemistry, 43, 4568, 10.1021/bi036022q

Dufour, 1995, Peptide aldehydes and nitriles as transition state analog inhibitors of cysteine proteases, Biochemistry, 34, 9136, 10.1021/bi00028a024

Eisman, 2011, Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect, J. Bone Miner. Res., 26, 242, 10.1002/jbmr.212

Villhauer, 2003, 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties, J. Med. Chem., 46, 2774, 10.1021/jm030091l

Wijkmans, 2011, Inhibitors of cathepsin K: a patent review (2004-2010), Expert Opin. Ther. Pat., 21, 1611, 10.1517/13543776.2011.616283

Emsley, 2010, Features and development of coot, Acta Crystallogr. D, 66, 486, 10.1107/S0907444910007493

Adams, 2010, PHENIX: a comprehensive python-based system for macromolecular structure solution, Acta Crystallogr. D, 66, 213, 10.1107/S0907444909052925